Soligenix Inc. (NASDAQ: SNGX), a biopharmaceutical company specializing in rare diseases, has been highlighted in a recent Zacks Small-Cap Research report for its anticipated key catalysts in the latter half of 2025. The report underscores the company’s progress in its phase 3 FLASH2 trial of HyBryte(TM) for early-stage cutaneous T cell lymphoma (CTCL), with an update on enrollment expected in the second half of 2025 and topline results anticipated in 2026.

Further clinical updates are expected in Q3 2025 for an investigator-initiated study evaluating extended HyBryte(TM) treatment, sponsored by Dr. Ellen Kim. Additionally, Soligenix is set to release topline results from its phase 2a trials for SGX302 in mild-to-moderate psoriasis and SGX945 in Behcet’s disease (BD) in the same quarter. These developments represent significant milestones in the company’s pipeline, offering potential breakthroughs in the treatment of rare diseases.

The Zacks report expresses optimism about Soligenix’s upcoming catalysts, particularly the IIS update’s implications for the FLASH2 trial’s success. The psoriasis and BD programs are also noted for their potential to exceed current market expectations, providing additional value not currently reflected in the company’s share price.

For more details on the report, visit https://ibn.fm/QFcH6.

This news story relied on content distributed by None. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Soligenix Inc. Anticipates Key Catalysts in 2025 for Rare Disease Treatments.